Crispr Therapeutics AG (NASDAQ:CRSP) traded down 6.2% on Tuesday following a dissappointing earnings announcement. The company traded as low as $85.48 and last traded at $86.40, 1,018,895 shares were traded during trading. A decline of 3% from the average session volume of 1,052,515 shares. The stock had previously closed at $92.12.

The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.35). The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $19.77 million. Crispr Therapeutics had a return on equity of 6.54% and a net margin of 15.73%. The company's revenue was down 86.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.01) EPS.

Several equities research analysts have recently issued reports on the stock. Canaccord Genuity raised their price objective on shares of Crispr Therapeutics from $80.00 to $84.00 and gave the stock a "buy" rating in a research note on Monday, June 15th. Needham & Company LLC lifted their price target on shares of Crispr Therapeutics from $84.00 to $105.00 and gave the stock a "buy" rating in a research note on Tuesday. Oppenheimer started coverage on shares of Crispr Therapeutics in a research note on Monday. They set a "buy" rating and a $105.00 price target on the stock. Piper Sandler reiterated an "overweight" rating and set a $104.00 price target on shares of Crispr Therapeutics in a research note on Friday, June 19th. Finally, Roth Capital lifted their price target on shares of Crispr Therapeutics from $100.00 to $105.00 and gave the stock a "buy" rating in a research note on Friday, June 19th. One analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company's stock. The company presently has a consensus rating of "Buy" and a consensus target price of $87.25.

In other Crispr Therapeutics news, CEO Samarth Kulkarni sold 10,693 shares of the firm's stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $65.28, for a total value of $698,039.04. Following the completion of the sale, the chief executive officer now owns 175,833 shares in the company, valued at approximately $11,478,378.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Tony W. Ho sold 7,158 shares of the business's stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $75.04, for a total transaction of $537,136.32. Following the completion of the transaction, the vice president now directly owns 40,676 shares of the company's stock, valued at $3,052,327.04. The disclosure for this sale can be found here. Over the last three months, insiders have sold 290,214 shares of company stock valued at $21,181,054. Company insiders own 17.10% of the company's stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Stratos Wealth Partners LTD. bought a new stake in shares of Crispr Therapeutics during the second quarter valued at approximately $313,000. Lenox Wealth Management Inc. grew its stake in shares of Crispr Therapeutics by 77.3% during the second quarter. Lenox Wealth Management Inc. now owns 3,898 shares of the company's stock valued at $286,000 after purchasing an additional 1,700 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Crispr Therapeutics by 23.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,445 shares of the company's stock valued at $1,723,000 after purchasing an additional 4,406 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its stake in shares of Crispr Therapeutics by 8.4% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,401 shares of the company's stock valued at $470,000 after purchasing an additional 498 shares during the last quarter. Finally, SeaCrest Wealth Management LLC bought a new stake in shares of Crispr Therapeutics during the second quarter valued at approximately $655,000. 57.93% of the stock is currently owned by institutional investors and hedge funds.

The company's 50 day moving average price is $78.76 and its 200 day moving average price is $59.40. The firm has a market capitalization of $5.41 billion, a P/E ratio of 115.20 and a beta of 2.35.

About Crispr Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: What Every Investor Needs to Understand About Secondary Public Offerings

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

12 Marijuana Stocks to Buy Now

There are now more than 50 publicly-traded companies operating in the cannabis industry. Most of these companies aren't directly growing and selling marijuana themselves, but they do stand to benefit greatly as more states legalize the sale and possession of marijuana. Some of these marijuana stocks are media companies. Others are privately studying the medical uses of marijuana. Yet others are providing tools and software for marijuana growers. As more cannabis companies file IPOs and enter the stock market, it will become increasingly difficult for investors to identify which marijuana stocks will truly benefit from the cannabis boom.

Our subscribers have begun digging through these companies, checking out their financials, business models and long-term growth prospects. They know that some "marijuana stocks" are just empty shell companies that deserve to be penny stocks, but they also recognize there are some legitimate and growing companies that truly stand to benefit from the green rush. As a group, they have added 10 different cannabis stocks to their watchlists and are actively investing in them. More than 1,400 MarketBeat subscribers are now following our top-trending cannabis company.

This slide show lists the 12 pot stocks that MarketBeat subscribers are have added to their watchlists and are actively monitoring.

View the "12 Marijuana Stocks to Buy Now".



Source link